EUVIMEDEUVIMED entdecken
Open Access

Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis

Kimberly S Lakin, John Spivack, Jessica K Gordon iD, Yaxia Zhang, Deanna Jannat-Khah iD, Hiranmayi Ravichandran, Niroshana Anandasabapathy, Dana E Orange, Robert F Spiera iD

Arthritis & Rheumatology · 2026-02 · 78 (2) · 418-427

DOI: 10.1002/art.43370 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, online erschienen am 20.11.2025. Verfasst von Kimberly S Lakin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Hospital for Special Surgery, New York City, New York. Hauptthemen laut MEDLINE: Skin, Scleroderma, Diffuse, Actins, Fibroblasts. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Scleroderma Foundation, Hospital for Special Surgery Research Institute Kellen Scholars Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the relationship of skin fibroblast CD34 and α‐smooth muscle actin (α‐SMA) and immune cell infiltration with disease duration in diffuse cutaneous systemic sclerosis (dcSSc) and identify predictors of improvement.

Methods

Skin biopsies and clinical data were analyzed from patients with dcSSc enrolled in lenabasum (n = 79), belimumab (n = 18), or nilotinib (n = 8) trials. CD34 and α‐SMA were scored semiquantitatively. Immune cells (CD20+, CD3+, and CD123+) were counted. Clinical and histologic features were compared between those with early (5‐point decrease in modified Rodnan skin score (mRSS) at 52 weeks. An Akaike's information criterion–optimal multiple logistic regression model for clinical improvement among 68 mycophenolate mofetil (MMF) users was developed. Fibroblast spatial organization was visualized using imaging mass cytometry (IMC) in a representative sample.

Results

Despite similar baseline mRSS, early disease was associated with lower CD34, higher α‐SMA, increased B cells, and greater mRSS improvement compared with later SSc. IMC demonstrated regions of CD34+ fibroblasts in superficial dermis and α‐SMA+ fibroblasts in deeper, collagen‐dense regions. Among MMF users, high CD34 and α‐SMA predicted improvement in early SSc; however, high α‐SMA predicted lower odds of improvement in later SSc. The probability of improvement was lowest in early SSc with α‐SMA low /CD34 low immunophenotype and later SSc with α‐SMA high . In later SSc, B cells were higher in α‐SMA high versus α‐SMA low skin.

Conclusion

Fibroblast immunophenotype varied by baseline disease duration and improved model performance for identifying those with improvement on MMF. Skin biopsies may be useful for refining prognosis and guiding patient management decisions. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SkinScleroderma, DiffuseActinsFibroblastsHumansFemaleMiddle AgedMaleBiopsyAntigens, CD34AdultB-LymphocytesMycophenolic AcidImmunosuppressive AgentsAged

Substanzen

ActinsAntigens, CD34Mycophenolic AcidImmunosuppressive AgentsACTA2 protein, human

Autor:innen und Institutionen

  • Hospital for Special Surgery, New York City, New York.
  • Weill Cornell Medicine, New York City, New York.
  • Department of Physiology and Biophysics, Institute for Computational Biomedicine, Weill Cornell Medicine, New York City, New York.
  • Caryl and Israel Englander Institute for Precision Medicine, Weill Cornell Medicine, New York City, New York.
  • Department of Dermatology; Department of Microbiology and Immunology, Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, New York City, New York.
  • Parker Institute for Cancer Immunotherapy and Sandra and Edward Meyer Cancer Center of Weill Cornell Medicine, New York City, New York.

ORCID-Profile: Jessica K Gordon, Deanna Jannat-Khah, Robert F Spiera

Förderung

  • NIAMS NIH HHS
  • National Scleroderma Foundation
  • Hospital for Special Surgery Research Institute Kellen Scholars Program
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases

Zitieren

APA

Lakin, K. S., Spivack, J., Gordon, J. K., Zhang, Y., Jannat-Khah, D., Ravichandran, H., Anandasabapathy, N., Orange, D. E., & Spiera, R. F. (2026). Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 78(2), 418-427. https://doi.org/10.1002/art.43370

Vancouver

Lakin KS, Spivack J, Gordon JK, Zhang Y, Jannat-Khah D, Ravichandran H, et al. Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology. 2026;78(2):418-427. doi:10.1002/art.43370

BibTeX
@article{Lakin2026,
  author = {Lakin, Kimberly S and Spivack, John and Gordon, Jessica K and Zhang, Yaxia and Jannat-Khah, Deanna and Ravichandran, Hiranmayi and Anandasabapathy, Niroshana and Orange, Dana E and Spiera, Robert F},
  title = {Skin Biopsies Enhance Prediction of Clinical Trajectory in Diffuse Cutaneous Systemic Sclerosis},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  volume = {78},
  number = {2},
  pages = {418--427},
  doi = {10.1002/art.43370}
}
Kostenlos starten →